Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01311388
First received: March 6, 2011
Last updated: March 8, 2011
Last verified: March 2011
  Purpose

The investigators want to achieve the goal of diagnosis in early phase, accurate treatment and existence for a long period in order to screen in early phase, diagnose in clinical trial, choose treatment and evaluate prognosis of cancers by establishing molecular pathology tools.


Condition
Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 1500
Study Start Date: August 2010
Estimated Study Completion Date: December 2013
Detailed Description:

This research is going to discuss the biomarker expression of common malignant neoplasm (tumor)among Taiwanese, such as large intestine rectal cancer, breast cancer, prostate gland cancer, lung cancer, oral cancer, gastric cancer, liver cancer, cervical cancer, cancer of the womb, ovarian cancer, carcinoma of urinary bladder, kidney cancer and so on.

The investigators hope to find the biomarker of common tumors among Taiwanese in order to develop the tools of tumor screening, diagnosis, treatment methods and prediction prognosis

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

cancer patients

Criteria

Inclusion Criteria:

  • above 20 years old
  • all kinds of cancer patients

Exclusion Criteria:

  • under 20 years old
  • none cancer patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01311388

Locations
Taiwan
TMU-CECR
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Wen-Ta Chiu TMU-CECR
  More Information

No publications provided

Responsible Party: Wen-Ta Chiu, Taipei Medical University-Center of Excellence For Cancer Research, TMU-CECR
ClinicalTrials.gov Identifier: NCT01311388     History of Changes
Other Study ID Numbers: 99049
Study First Received: March 6, 2011
Last Updated: March 8, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
cancer

ClinicalTrials.gov processed this record on April 17, 2014